Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

dr. e. gräub ag - equine-derived aseptic serum containing antibodies (immune serum) against actinobacillus (a.) equuli, streptococcus (sc.) equi spp. zooepidemicus, salmonella (s.) abortus equi, escherichia (e.) coli - injektionslösung für fohlen und jährlinge - equine-derived aseptic serum containing antibodies (immune serum) against actinobacillus (a.) equuli, streptococcus (sc.) equi spp. zooepidemicus, salmonella (s.) abortus equi, escherichia (e.) coli, phenolum max. 0.5%. - immunglobuline gegen actionobacillus equuli, strepotcoccus equi, salmonella abortus equi und e. coli für fohlen und jährlinge - andere immunologische arzneimittel

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

dr. e. gräub ag - colostral gamma globulins, antibodies against e. coli 78:80 b, colostral gamma globulins, antibodies against e. coli k99, colostral gamma globulins, antibodies against coronavirus, colostral gamma globulins, antibodies against rotavirus - lösung für kälber - colostral gamma globulins, antibodies against e. coli 78:80 b 1/160 u., colostral gamma globulins, antibodies against e. coli k99 1/1600 u., colostral gamma globulins, antibodies against coronavirus 1/1600 u., colostral gamma globulins, antibodies against rotavirus 1/3200 u., phenolum max. 5 mg, aqua, aqua ad iniectabile, ad solutionem pro 1 ml. - kolostrale immunglobuline für kälber - andere immunologische arzneimittel

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

msd animal health gmbh - horse proteins, antibodies against tetanus - injektionslösung für pferde, schafe und ziegen - horse proteins max. 170 mg, antibodies against tetanus min. 1160 u., phenolum max. 5 mg, natrii chloridum, aqua ad iniectabile, ad solutionem pro 1 ml. - antiserum gegen tetanus für pferde, schafe und ziegen - andere immunologische arzneimittel

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

biokema s.a. - antibodies against escherichia coli cs31a, antibodies against escherichia coli k99 (f5), antibodies against escherichia coli o101, antibodies against escherichia coli o9, antibodies against escherichia coli o8, antibodies against escherichia coli o78, antibodies against escherichia coli o15, antibodies against escherichia coli o117, antibodies against escherichia coli o115, antibodies against escherichia coli o86, antibodies against escherichia coli f41, antibodies against escherichia coli att25 (f17), antibodies against the rotavirus, antibodies against the coronavirus - solution buvable pour veaux, agneaux, porcelets et cabris - antibodies against escherichia coli cs31a ≥ 3.1 log10 u., antibodies against escherichia coli k99 (f5) ≥ 2.8 log10 u., antibodies against escherichia coli o101 > 1‘600 u., antibodies against escherichia coli o9 > 1‘600 u., antibodies against escherichia coli o8 > 1‘600 u., antibodies against escherichia coli o78 > 1‘600 u., antibodies against escherichia coli o15 > 1‘600 u., antibodies against escherichia coli o117 > 1‘600 u., antibodies against escherichia coli o115 > 1‘600 u., antibodies against escherichia coli o86 > 1‘600 u., antibodies against escherichia coli f41 > 1‘600 u., antibodies against escherichia coli att25 (f17) > 1‘600 u., antibodies against the rotavirus > 1‘600 u., antibodies against the coronavirus > 1‘600 u., e 218 ≤ 0.8 mg/ml, ad solutionem pro 1 ml. - immunoglobulines pour veaux, agneaux, porcelets et cabris - andere immunologische arzneimittel

Schweiz - Deutsch - Tierarzneimittel Kompendium der Schweiz (Institut für Veterinärpharmakologie und toxikologie)

biokema s.a. - antibodies against escherichia coli cs31a, antibodies against escherichia coli k99 (f5), antibodies against escherichia coli o101, antibodies against escherichia coli o9, antibodies against escherichia coli o8, antibodies against escherichia coli o78, antibodies against escherichia coli o15, antibodies against escherichia coli o117, antibodies against escherichia coli o115, antibodies against escherichia coli o86, antibodies against escherichia coli f41, antibodies against escherichia coli att25 (f17), antibodies against the rotavirus, antibodies against the coronavirus - solution injectable pour veaux et agneaux - antibodies against escherichia coli cs31a ≥ 3.1 log10 u., antibodies against escherichia coli k99 (f5) > 2‘560 u., antibodies against escherichia coli o101 > 1‘920 u., antibodies against escherichia coli o9 > 1‘920 u., antibodies against escherichia coli o8 > 1‘920 u., antibodies against escherichia coli o78 > 1‘920 u., antibodies against escherichia coli o15 > 1‘920 u., antibodies against escherichia coli o117 > 1‘920 u., antibodies against escherichia coli o115 > 1‘920 u., antibodies against escherichia coli o86 > 1‘920 u., antibodies against escherichia coli f41 > 1‘920 u., antibodies against escherichia coli att25 (f17) > 1‘920 u., antibodies against the rotavirus > 1‘920 u., antibodies against the coronavirus > 1‘920 u., phenolum ≤ 4.0 mg/ml, ad solutionem pro 1 ml. - immunoglobulines pour veaux et agneaux - andere immunologische arzneimittel

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europäische Union - Deutsch - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. anfänge der immunität wurden 1 woche nach der grundimmunisierung für rhinotracheitis, calicivirus und chlamydophila felis nachgewiesen. die dauer der immunität beträgt 1 jahr nach der letzten (re-) impfung.

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Deutsch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologischen arzneimitteln für felidae, - katzen - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. anfänge der immunität wurden eine woche nach der grundimmunisierung für rhinotracheitis, calicivirus, chlamydophila felis und panleukopenie nachgewiesen. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.